ALKERMES | ALKS - Capitaux D'Emprunt

Prix De L'Action
37.48
Variation Quotidienne
-0.88 -2.29%
Mensuellement
11.00%
Annuel
19.29%
Q2 Prévisions
36.35




Capitaux D'Emprunt Changement Date
AbbVie USD 58.94B 4.03B 2025-12
Acadia Pharmaceuticals USD 0 0 2025-03
ALKERMES USD 1.48B 1.2B 2026-03
Amgen USD 51.89B 1.88B 2026-03
Biogen USD 6.29B 1.7M 2026-03
BioMarin Pharmaceutical USD 1.43B 833.11M 2026-03
Bristol-Myers Squibb USD 42.15B 698M 2026-03
Coherus Biosciences USD 51.08M 496K 2025-12
Eli Lilly USD 39.37B 1.5B 2026-03
Gilead Sciences USD 20.86B 1.27B 2026-03
Heron Therapeutics USD 140.64M 975K 2025-12
Ionis Pharmaceuticals USD 1.91B 9M 2026-03
J&J USD 37.53B 1.91B 2026-03
Malin Corporation EUR 0 0 2024-12
Merck USD 46.67B 77M 2026-03
Minerva Neurosciences USD 0 86.58M 2024-09
Nektar Therapeutics USD 63.16M 44.35M 2025-12
Neurocrine Biosciences USD 169.5M 500K 2023-03
Otsuka Holdings JPY 164.96B 1.96B 2026-03
Ovoca Bio EUR 0 0 2021-06
Pfizer USD 60.57B 1.08B 2026-03
Regeneron Pharmaceuticals USD 1.99B 719.7M 2026-03
Vertex Pharmaceuticals USD 106.7M 4.7M 2025-12